Because the study was clinic based and included a relatively small number of subjects with type 2 diabetes (n ϭ 68), we present our findings from a nationwide screening program, which was conducted between 1992 and 1997 for all schoolchildren aged 6 -18 years (2) . Diabetes was diagnosed in 381 boys and 454 girls whose fasting blood glucose exceeded 7 mmol/l. Type 1 diabetes was considered if they received insulin therapy within 6 months and if it was confirmed by their referred physicians (2). Type 2 diabetes was considered if they were under diet control or were currently receiving oral antidiabetic agents without recurrent diabetic ketoacidosis. Those who received insulin injection within 3 years were excluded due to uncertainty in the classification of diabetes. Overweight and obesity were defined by 85th to 95th and above 95th percentile of age-and sexspecific cutoffs, whereas hypertension was diagnosed if systolic or diastolic blood pressure was Ͼ95th percentile of age-and sex-specific cutoffs in our population.
There were 330 subjects with type 1 diabetes and 505 subjects with type 2 diabetes. Hypertension was more prevalent in adolescents with type 2 than type 1 diabetes (44.4 vs. 23.4%, P Ͻ 0.001), which is similar to the report by Eppens et al. (1) . After adjusting for age and sex, subjects with type 2 diabetes also showed a higher risk of hypertension (odds ratio 2.25 [95% CI 1.59 -3.20], P Ͻ 0.001).
Similar to the findings by Eppens et al., adolescents with type 2 diabetes had a higher rate of obesity in our population (45.4 vs. 8.8%, P Ͻ 0.001). However, we found a higher rate of overweight in those with type 2 diabetes (10.1 vs. 7.2%, P Ͻ 0.001), which was not observed by Eppens et al. When applying the same definition of overweight and obesity (3), as Eppens et al. did, adolescents with type 2 diabetes also showed a higher rate of both overweight and obesity (overweight 28.6 vs. 15.0%, P Ͻ 0.001; obesity 30.0 vs. 7.2%, P Ͻ 0.001).
The findings of our population-based study support and extend the observations by Eppens et al., showing that adolescents with type 2 diabetes were more obese and had a higher rate of hypertension than those with type 1 diabetes. • (2) . More data exist regarding the safety of metformin in pregnancy, even though it is not recommended as an oral hypoglycemic agent in diabetic pregnancy (3, 4) .
HUNG-YUAN LI
We report two case subjects of type 2 diabetic women who used repaglinide at conception and during the first 6 -7 weeks of an unplanned pregnancy.
The first patient, L.M., was 38 years old and was diagnosed with type 2 diabetes when she was 31; since 2004, she had been treated with repaglinide (1.5 mg/ day) and metformin (3 g/day). When we first visited her, she was 6 weeks and 4 days into her second pregnancy, with a pregestational BMI of 26.2 kg/m 2 . The second patient, N.G., was 34 years old, developed diabetes in 2001, and had been treated with repaglinide (2.5 mg/day) for 2 years. When we first visited her, she was nulliparous at the 6th gestational week, with a pregestational BMI of 21.3 kg/m 2 . Both gestational ages were confirmed by ultrasound. Neither patient had evidence of micro-and macrovascular complications or autonomic neuropathy. Due to the lack of data on the safety of repaglinide in pregnancy, they were both switched to insulin. Other therapies included a multivitamin and mineral supplementation.
L.M. was given alfa metildopa begin-ning with the 29th week of gestation to treat gestational hypertension. At 40 weeks and 3 days, she spontaneously delivered a healthy female newborn (3,680 g, length 52 cm, cranial circumference [CC] 33 cm, and Apgar score 9/10) who developed jaundice, needing phototherapy for 1 day. N.G. submitted to a cesarean section at her 39th gestational week and had a male newborn (2,650 g, length 45 cm, CC 33.5 cm, and Apgar score 9/10).
Both birth weights were adequate for the gestational ages, and no congenital malformations were observed. Six weeks later, they did not report neonatal or maternal morbidity.
Our experience regarding the use of repaglinide in pregnancy is limited to these two subjects, whose unplanned conception was with a good HbA 1c (L.M. preconception 6.8%, conception 7%, and 3rd trimester 5.6%; N.G. conception 6.4% and 3rd trimester 5.1%; normalized variance 3-6%) obtained with the use of repaglinide from several months before conception until early pregnancy.
Repaglinide did not affect embryo development; no minor or major malformations were observed. Because of its early discontinuation, we have no data about its influence on fetal growth.
These observations do not allow us to draw any conclusions about the effects and risks of repaglinide in pregnancy. (1-3) . Recently, Hara et al. (3) demonstrated that the ratio of HMW adiponectin to total adiponetin (HMWR) in systemic circulation is useful for the prediction of insulin resistance and metabolic syndrome.
ANGELA NAPOLI
Metabolically obese, normal-weight (MONW) subjects (BMI Ͻ25 kg/m 2 ) are characterized by excess visceral fat area (VFA; Ն100 cm 2 by abdominal computed tomography scanning) and insulin resistance (4 -6) . In addition, we previously demonstrated that the plasma level of total adiponectin is significantly associated with insulin resistance and hyperinsulinemia in Japanese MONW men with normal glucose tolerance (NGT) (6). However, the relationship of HMWR with insulin resistance has not yet been evaluated in Japanese MONW men with NGT.
The present study comprised 24 Japanese MONW (mean [ϮSE] 2 ) with NGT. The serum levels of HMW and total adiponectin were measured using a commercially available enzyme-linked immunosorbent assay kit (Daiichi Pure Chemicals, Ibaraki, Japan) (7).
The serum levels of HMW (1.260 Ϯ 0.152 vs. 1.791 Ϯ 0.172 g/ml, P Ͻ 0.05) and total (4.593 Ϯ 0.307 vs. 5.680 Ϯ 0.395 g/ml, P Ͻ 0.05) in MONW men were significantly decreased compared with normal men. HMWR was significantly decreased in MONW subjects (0.261 Ϯ 0.018, P Ͻ 0.05) compared with normal subjects (0.321 Ϯ 0.023). The glucose infusion rate (GIR; index of insulin resistance during the euglycemic-hyperinsulinemic clamp study) in MONW subjects (50.2 Ϯ 2.1 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 , P Ͻ 0.01) was significantly decreased compared with normal subjects (62.8 Ϯ 0.3 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ). The serum levels of HMW (r ϭ 0.491, P Ͻ 0.05) and total (r ϭ 0.414, P Ͻ 0.05) adiponectin were significantly correlated with GIR in MONW subjects. Significant correlation was observed between HMWR and GIR (r ϭ 0.454, P Ͻ 0.05) in MONW men. This is the first report that demonstrates the relationship of HMWR with insulin resistance in Japanese MONW men with NGT. In our present study, three of the MONW subjects had hypertriglyceridemia (Ն1.7 mmol/l) and nine men had arterial hypertension (blood pressure Ն130/85 mmHg), but the remaining subjects showed no low HDL cholesterol (Ͻ1.0 mmol/l). Based on these findings, these subjects are considered to have premetabolic syndrome (8). This clinical condition should be diagnosed at early stages to prevent the progression of oxidative stress and the occurrence of obesity-related complications (9). The results of this study showed that in addition to total serum levels of adiponectin, HMWR should also be evaluated for screening and early diagnosis of insulin resistance in Japanese MONW subjects with NGT. 
